The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs

Stefan D. Baral, Susanne Strömdahl, Chris Beyrer

Research output: Contribution to journalReview article

Abstract

PURPOSE OF REVIEW: Oral preexposure prophylaxis (PrEP) has shown HIV preventive efficacy for several key populations at risk for HIV infection including MSM and heterosexual men and women in HIV serodiscordant relationships. An efficacy trial of daily oral tenofovir among people who inject drugs (IDU) is underway in Thailand. RECENT FINDINGS: Although efficacy data is pending, there is emerging biological and public health plausibility data suggesting the utility of PrEP as an effective component of combination HIV prevention for IDU. Drawing from studies characterizing adherence to antiretroviral therapy for IDU, there are a range of scientific and operational considerations for the potential use of PrEP for IDU. We review here the available literature on the potential use of PrEP for IDU, barriers to uptake and adherence, and potential implementation science questions, which could address, and potently increase, the effectiveness of this intervention. SUMMARY: IDU remain the most underserved population in the HIV response worldwide, and have a marked gap in prevention services, making PrEP a potentially promising addition to the prevention toolkit for people who use drugs and, for those already living with HIV infection, for their spouses and other sexual partners.

Original languageEnglish (US)
Pages (from-to)563-568
Number of pages6
JournalCurrent opinion in HIV and AIDS
Volume7
Issue number6
DOIs
StatePublished - Nov 1 2012

    Fingerprint

Keywords

  • HIV
  • injecting drug user
  • preexposure prophylaxis
  • prevention

ASJC Scopus subject areas

  • Immunology
  • Hematology
  • Oncology
  • Oncology(nursing)
  • Infectious Diseases
  • Virology

Cite this